Compare SOHU & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | TTRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 298.8M |
| IPO Year | 2018 | 2025 |
| Metric | SOHU | TTRX |
|---|---|---|
| Price | $12.83 | $15.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.00 | $8.00 |
| AVG Volume (30 Days) | 61.1K | ★ 113.8K |
| Earning Date | 05-18-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $2.57 |
| 52 Week High | $17.30 | $16.45 |
| Indicator | SOHU | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 73.81 |
| Support Level | $11.61 | $3.68 |
| Resistance Level | $13.71 | N/A |
| Average True Range (ATR) | 0.49 | 1.42 |
| MACD | -0.13 | 0.33 |
| Stochastic Oscillator | 21.92 | 81.74 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.